AnaptysBio (NASDAQ:ANAB) Hits New 12-Month High on Analyst Upgrade

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price hit a new 52-week high during mid-day trading on Wednesday after Stifel Nicolaus raised their price target on the stock from $56.00 to $85.00. Stifel Nicolaus currently has a buy rating on the stock. AnaptysBio traded as high as $58.50 and last traded at $58.47, with a volume of 202416 shares traded. The stock had previously closed at $52.83.

Other equities research analysts also recently issued reports about the stock. Barclays upped their target price on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday. Truist Financial upped their price objective on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. UBS Group initiated coverage on AnaptysBio in a research note on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.89.

Insider Activity

In other news, Director Magda Marquet sold 11,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the transaction, the director directly owned 9,930 shares of the company’s stock, valued at approximately $478,923.90. This represents a 52.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Faga sold 15,309 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $662,267.34. Following the sale, the chief executive officer directly owned 458,139 shares in the company, valued at $19,819,093.14. This trade represents a 3.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 156,280 shares of company stock worth $7,254,939. 33.50% of the stock is currently owned by company insiders.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long‑range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin‑off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short‑term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short‑interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short‑interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit‑taking or rotation away from a stock that recently traded near its 1‑year high; that technical flow can drive near‑term downside even with favorable analyst commentary.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANAB. Smartleaf Asset Management LLC boosted its holdings in shares of AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares in the last quarter. Larson Financial Group LLC lifted its position in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in AnaptysBio by 24.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 263 shares in the last quarter. Bessemer Group Inc. boosted its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 1,383 shares during the last quarter.

AnaptysBio Price Performance

The stock has a 50-day moving average price of $50.17 and a 200 day moving average price of $38.78. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -110.15 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The firm had revenue of $108.25 million during the quarter, compared to analysts’ expectations of $87.09 million. As a group, equities research analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has authorized a share buyback program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.